Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05926024 2026-03-11

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Active not recruiting

253 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

Phase NA Recruiting

160 enrolled

Breast

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

325 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07164872 2025-09-10

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

Phase NA Not yet recruiting

50 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT07166185 2025-09-10

NEOTRAPSCAL

Recruiting

70 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

180 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

Clinical Trials

N01-A-PICIT-GT

I-SPY

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

NEOTRAPSCAL

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC